Abstract 2761: A two-stage evaluation of genetic variation in immune and inflammation genes and risk of non-Hodgkin lymphoma (NHL)

Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: NHL is a malignancy of lymphocytes, and there is growing evidence for a role of immune dysfunction in the etiology of this malignancy. We conducted a 2-stage analysis of single nucleotide polymorphisms (SNPs) from 1,253 genes using the ParAllele (now Affymetrix) Immune and Inflammation Panel with risk of NHL. Methods: In Stage 1, we successfully genotyped 7,670 SNPs in a clinic-based study of 425 NHL cases and 465 frequency matched controls seen at the Mayo Clinic. Genes were tagged with SNPs from HapMap to provide coverage at r2 = 0.8 and minor allele frequency (MAF) >0.05. In Stage 2, we genotyped the top 768 SNPs on an additional 584 cases and 768 controls from the Mayo Clinic Study, and then conducted a pooled analysis of all 1009 cases and 1233 controls. The association of individual SNPs with NHL risk was assessed using the Odds Ratios (ORs) and 95% confidence intervals, adjusted for age and gender. The most prevalent homozygous genotype was used as the reference group, and each SNP was modeled individually as having a log-additive effect. Results: Overall, the mean age at diagnosis was 62.0 years for cases and the mean age at enrollment for controls was 61.1 years. The most common subtypes were chronic lymphocytic leukemia (CLL, N=343), follicular lymphoma (FL, N=245), and diffuse large B-cell lymphoma (DLBCL, N=178). In the pooled analysis, there were 3 SNPs at p<0.0004. The top SNP was [rs241447][1] (MAF=0.26) from TAP2 at 6p21.3 (OR=1.34, 95% CI 1.17-1.53, p=0.00003). This SNP is a cSNP that leads to a missense change (Ala→Thr). The second SNP was rs2857597 (MAF=0.26) from AIF1, also at 6p21.3 (OR=0.77, 95% CI 0.67-0.88, p=0.0002). The region spanning these two SNPs had multiple risk SNPs with p<0.01, including SNPs in BAT2 (rs3132453), BAT3 (rs2242656), C2 (rs7746553), HLA-DRA (rs8084, rs7192), and TAP2 (rs1894408). Of these SNPs, only [rs241447][1] (TAP2) and rs7192 (HLA-DRA) displayed any substantial LD (r2=0.84, all other r2<0.25). The third SNP was [rs754505][2] (MAF=0.07) from NFATC1 at 18q23 (OR=0.63, 95% CI 0.49-0.81, p=0.0003). There were 4 additional SNPs in this gene with a p<0.05 (rs7240932, [rs396127][3], [rs177820][4], [rs183374][5]). In subtype analysis, the SNPs from 6p21.3 showed the strongest associations with FL (including the TAP2 SNP [rs241447][1], p=6.9 × 10−8), although there were also associations with CLL (except for the TAP2 and C2 SNPs) and DLBCL (except for the HLA-DRA SNPs). For NFATC1 the associations were similar across the main NHL subtypes. Conclusions: We identified strong associations with NHL risk in the 6p21.3 region, which includes the MHC locus. Our results were particularly striking for FL and supports recent GWAS and candidate gene studies that implicate this region. We also identified NFATC1 as a susceptibility gene. NFATC1 is known to regulate the expression of growth and survival genes including MYC, TNF, CD40L, and BAFF, all of which have also been linked to lymphomagenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2761. doi:10.1158/1538-7445.AM2011-2761 [1]: /lookup/external-ref?link_type=GEN&access_num=rs241447&atom=%2Fcanres%2F71%2F8_Supplement%2F2761.atom [2]: /lookup/external-ref?link_type=GEN&access_num=rs754505&atom=%2Fcanres%2F71%2F8_Supplement%2F2761.atom [3]: /lookup/external-ref?link_type=GEN&access_num=rs396127&atom=%2Fcanres%2F71%2F8_Supplement%2F2761.atom [4]: /lookup/external-ref?link_type=GEN&access_num=rs177820&atom=%2Fcanres%2F71%2F8_Supplement%2F2761.atom [5]: /lookup/external-ref?link_type=GEN&access_num=rs183374&atom=%2Fcanres%2F71%2F8_Supplement%2F2761.atom